Related references
Note: Only part of the references are listed.Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Michael R. Loebinger et al.
CANCER RESEARCH (2009)
TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Thomas S. Griffith et al.
CURRENT GENE THERAPY (2009)
In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas
Mahmud Uzzaman et al.
NEURO-ONCOLOGY (2009)
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
Laura S. Sasportas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Human Bone Marrow-Derived Mesenchymal Stromal Cells Expressing S-TRAIL as a Cellular Delivery Vehicle for Human Glioma Therapy
Lata G. Menon et al.
STEM CELLS (2009)
Gene Therapy Using TRAIL-Secreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma
Seong Muk Kim et al.
CANCER RESEARCH (2008)
Stem and progenitor cell-mediated tumor selective gene therapy
K. S. Aboody et al.
GENE THERAPY (2008)
Migratory neighbors and distant invaders: tumor-associated niche cells
Jared Wels et al.
GENES & DEVELOPMENT (2008)
Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model
Andrea Mohr et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
Avi Ashkenazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
Lin Cao et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Dylan Daniel et al.
BLOOD (2007)
Engineering targeted viral vectors for gene therapy
Reinhard Waehler et al.
NATURE REVIEWS GENETICS (2007)
The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis
Isabelle Petit et al.
TRENDS IN IMMUNOLOGY (2007)
Highly efficient gene transfer into mobilized CD34+ hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent
Cristiana Lavazza et al.
EXPERIMENTAL HEMATOLOGY (2007)
Targeting TRAIL agonistic receptors for cancer therapy
Carmelo Carlo-Stella et al.
CLINICAL CANCER RESEARCH (2007)
Niche-to-niche migration of bone-marrow-derived cells
Rosandra N. Kaplan et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand
Carmelo Carlo-Stella et al.
HUMAN GENE THERAPY (2006)
Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4
Simon P. Fricker et al.
BIOCHEMICAL PHARMACOLOGY (2006)
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology
Giorgio Zauli et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature
H Jin et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
JA Burger et al.
BLOOD (2006)
Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis
M Kucia et al.
STEM CELLS (2005)
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature
JN Rybak et al.
NATURE METHODS (2005)
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing Jurkat cells
A Ballestrero et al.
CLINICAL CANCER RESEARCH (2004)
Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
H Jin et al.
CANCER RESEARCH (2004)
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
S Inoue et al.
CELL DEATH AND DIFFERENTIATION (2004)
Endothelial cells in the bone marrow of patients with multiple myeloma
A Vacca et al.
BLOOD (2003)
Vascular and haematopoietic stem cells:: Novel targets for anti-angiogenesis therapy?
S Rafii et al.
NATURE REVIEWS CANCER (2002)
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours
PB Vermeulen et al.
EUROPEAN JOURNAL OF CANCER (2002)
Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery?
K Harrington et al.
HUMAN GENE THERAPY (2002)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Share Paper
